Q-omics provides the consensus-scored LRRC23 profile across patient tissues and cancer cell-line models. LRRC23 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LRRC23 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, LRRC23 RNA expression shows 17,747 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight SKCM, KIRC, and KICH as cancer lineages where LRRC23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC23 survival associations across molecular data types. LRRC23 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC23 RNA expression–survival associations across cancer types. High LRRC23 expression shows unfavorable associations in COAD, but favorable associations in SKCM, BRCA, UVM, KIRP and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LRRC23 RNA expression.
This table summarizes LRRC23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRC23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC23 shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher LRRC23 RNA expression in tumor versus normal tissue (log2 FC = +0.864, t-test p < 0.001).
This table shows molecular features associated with LRRC23 in patient tissues and cancer cell lines. In patient samples, LRRC23 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
